LYEL
Lyell Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.37
+0.35%0
Insider buys (3m)
14
Insider sells (3m)
-$245.5K
Net value (3m)
+19.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 25, 2026 | Hill Stephen J. · officer: Chief Operating Officer | Sale | 989 | $16 |
| Aug 25, 2026 | Lee Gary K. · officer: Chief Scientific Officer | Sale | 1,457 | $16 |
| Aug 25, 2026 | Seely Lynn · director, officer: President and CEO | Sale | 9,589 | $16 |
| Aug 11, 2026 | Lee Gary K. · officer: Chief Scientific Officer | Sale | 131 | $14 |
| Aug 11, 2026 | Bulis Veronica Sanchez · officer: VP, Corporate Controller | Sale | 621 | $14 |
| Aug 11, 2026 | Seely Lynn · director, officer: President and CEO | Sale | 390 | $14 |
| Aug 11, 2026 | Hill Stephen J. · officer: Chief Operating Officer | Sale | 89 | $14 |
| Jul 20, 2026 | Innovative Cellular Therapeutics Holdings Ltd · 10 percent owner | Sale | 10 | $14 |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd · 10 percent owner | Sale | 10 | $14 |
| Jun 15, 2026 | Seely Lynn · director, officer: President and CEO | Sale | 388 | $19 |
| Jun 15, 2026 | Bulis Veronica Sanchez · officer: VP, Corporate Controller | Sale | 217 | $19 |
| Jun 15, 2026 | Hill Stephen J. · officer: Chief Operating Officer | Sale | 89 | $19 |
| Jun 15, 2026 | Lee Gary K. · officer: Chief Scientific Officer | Sale | 130 | $19 |
| Jun 12, 2026 | Bachleda Mark · director | A-Award | 9,250 | $13 |
| Jun 12, 2026 | NABEL ELIZABETH G · director | A-Award | 9,250 | $13 |
| Jun 12, 2026 | Klausner Richard · director | A-Award | 9,250 | $13 |
| Jun 12, 2026 | RIEFLIN WILLIAM JL · director | A-Award | 9,250 | $13 |
| Jun 12, 2026 | Ramachandra Sumant · director | A-Award | 9,250 | $13 |
| Jun 12, 2026 | FRIEDMAN CATHY · director | A-Award | 9,250 | $13 |
| Jun 12, 2026 | BRAWLEY OTIS W · director | A-Award | 9,250 | $13 |
| Jun 11, 2026 | Shook David · officer: Chief Medical Officer | Sale | 1,977 | $13 |
| Mar 16, 2026 | Shah Smital · officer: Chief Fin. and Bus. Officer | A-Award | 140,000 | $26 |
| Mar 9, 2026 | ARCH Venture Partners IX, LLC · 10 percent owner | Purchase | 488,090 | $26 |
| Mar 9, 2026 | ARCH Venture Fund XIII, L.P. · 10 percent owner | Purchase | 488,090 | $26 |
| Feb 12, 2026 | Seely Lynn · director, officer: President and CEO | Sale | 7,455 | $23 |
| Feb 12, 2026 | Lee Gary K. · officer: Chief Scientific Officer | Sale | 1,671 | $23 |
| Feb 12, 2026 | Hill Stephen J. · officer: Chief Operating Officer | Sale | 1,236 | $23 |
| Feb 11, 2026 | Hill Stephen J. · officer: Chief Operating Officer | A-Award | 65,000 | $24 |
| Feb 11, 2026 | Hill Stephen J. · officer: Chief Operating Officer | A-Award | 4,000 | $0.00 |
| Feb 11, 2026 | Hill Stephen J. · officer: Chief Operating Officer | Sale | 109 | $23 |
Institutional positioning
13F filings over the trailing two quarters
New 20Increased 23Reduced 11Sold out 75
| Filer | Action | Shares | Filed |
|---|---|---|---|
| ARCH VENTURE MANAGEMENT, LLC | Increased | 3,247,162 | May 15, 2026 |
| GSK PLC | Unchanged | 1,512,659 | May 14, 2026 |
| FORESITE CAPITAL MANAGEMENT IV, LLC | Unchanged | 800,399 | May 15, 2026 |
| ORLAND PROPERTIES LTD | Unchanged | 754,698 | May 6, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 718,155 | May 15, 2026 |
| ALMITAS CAPITAL LLC | Unchanged | 577,807 | May 15, 2026 |
| FORESITE CAPITAL MANAGEMENT V, LLC | Unchanged | 477,078 | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 458,905 | May 15, 2026 |
| CITADEL ADVISORS LLC | Increased | 393,462 | May 15, 2026 |
| VENBIO PARTNERS LLC | Unchanged | 337,697 | May 15, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Increased | 310,198 | May 15, 2026 |
| ALPHABET INC. | Unchanged | 293,256 | May 8, 2026 |
| BLACKROCK, INC. | Increased | 191,820 | May 13, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 166,980 | May 15, 2026 |
| SC CHINA HOLDING LTD | Unchanged | 152,299 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 25, 2026